Benralizumab: Targeted Therapy for Severe Asthma Relief

Key Points About Benralizumab Treatment

Benralizumab is a prescription medication designed to treat conditions associated with elevated eosinophil levels, a type of white blood cell involved in inflammation. It is most commonly prescribed for eosinophilic asthma and other eosinophilic disorders. This biologic therapy works by reducing eosinophil counts in the body, which helps control inflammation and alleviate symptoms. Before starting or adjusting your dosage, it’s essential to consult your healthcare provider. For personalized care, you may also consider scheduling a telemedicine visit with one of our providers.

Medication Names: Benralizumab and Fasenra

US Brand Name: Fasenra (benralizumab)

The term “benralizumab” refers to the active ingredient in the medication, while “Fasenra” is the brand name given by the manufacturer. Both names are commonly used when discussing treatment options for severe asthma and other eosinophilic conditions.

Pharmacologic Category of Benralizumab

Benralizumab belongs to the following pharmacologic categories:

1. Monoclonal Antibody
2. Interleukin-5 Receptor Antagonist

Benralizumab Dosing Guidelines

Benralizumab is prescribed for a variety of conditions in adults, with dosing schedules tailored to the specific condition being treated. Always follow your healthcare provider’s instructions and consult them before making any changes to your medication regimen.

Asthma Treatment

Dosage: 30 mg injected subcutaneously (under the skin) every 4 weeks for the first 3 doses, followed by every 8 weeks. This schedule is commonly used to manage eosinophilic asthma.

Eosinophilic Esophagitis

Dosage: 30 mg injected subcutaneously every 4 weeks. The duration of treatment may vary based on your doctor’s recommendations.

Chronic Rhinosinusitis with Nasal Polyps

Dosage: 30 mg injected subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.

Hypereosinophilia

Dosage: 30 mg injected subcutaneously every 4 weeks. Your doctor may adjust the frequency depending on your response to treatment.

Atopic Dermatitis

Dosage: 30 mg injected subcutaneously every 4 weeks. Adjustments to the treatment plan may be made based on symptom control.

Chronic Obstructive Pulmonary Disease (COPD)

Dosage: 30 mg injected subcutaneously every 4 weeks for the first 3 doses, followed by every 8 weeks.

Allergic Rhinitis

Dosage: 30 mg injected subcutaneously every 4 weeks. The length of treatment may vary.

Systemic Lupus Erythematosus

Dosage: 30 mg injected subcutaneously every 4 weeks. Your doctor will determine the appropriate treatment duration based on your condition.

Granulomatosis with Polyangiitis

Dosage: 30 mg injected subcutaneously every 4 weeks. Adjustments may be made depending on your response to therapy.

Churg-Strauss Syndrome

Dosage: 30 mg injected subcutaneously every 4 weeks. Your doctor will guide the length of treatment based on your needs.

It is crucial to consult your healthcare provider before making any changes to your medication regimen. If you need additional support, our telemedicine providers are available to assist you.

Dosage Forms and Strengths of Benralizumab

Benralizumab is available in the following forms:

1. Pre-filled syringe: 30 mg/mL
2. Pre-filled autoinjector (Fasenra Pen): 30 mg/mL

How to Administer Benralizumab

Benralizumab is administered as a subcutaneous injection, meaning it is injected just beneath the skin. Common injection sites include the upper arm, thigh, or abdomen. A healthcare provider may train you to administer the injection yourself at home, or you can receive it in a medical setting. It’s important to carefully follow your healthcare provider’s instructions to ensure proper administration.

If you have any questions or concerns about using Benralizumab, consider scheduling a telemedicine visit with one of our providers for additional guidance. Proper administration is key to effectively managing conditions such as severe asthma and eosinophilic disorders.

Contraindications for Benralizumab Treatment

A contraindication refers to a specific condition or circumstance in which a medication, such as Benralizumab, should not be used due to potential risks. If you have any of the following conditions, it is important to avoid Benralizumab treatment unless explicitly recommended by your healthcare provider.

Allergic reaction to Benralizumab or its ingredients: If you have ever experienced a severe allergic reaction (such as anaphylaxis) to Benralizumab or any of its components, this medication should not be used. Symptoms of an allergic reaction may include difficulty breathing, swelling, or a rash, all of which can be life-threatening. Notify your healthcare provider immediately if you suspect an allergic reaction.

Parasitic infections: Benralizumab may impair your immune system’s ability to fight parasitic infections. If you currently have a parasitic infection, your healthcare provider will likely treat the infection before initiating Benralizumab therapy to minimize potential complications.

Current or recent infections: If you have an active infection or a history of frequent infections, Benralizumab could further reduce your body’s ability to combat these illnesses. Be sure to discuss any ongoing or past infections with your healthcare provider before starting this biologic therapy for asthma.

Drug-to-Drug Interactions with Benralizumab

Although Benralizumab has relatively few known drug interactions, it is crucial to inform your healthcare provider about all medications you are currently taking. This includes prescription drugs, over-the-counter medications, supplements, and herbal products. The following treatments may interact with Benralizumab:

Live vaccines: Vaccines containing live viruses, such as the MMR (measles, mumps, and rubella) vaccine or the nasal flu vaccine, may be less effective while you are undergoing Benralizumab treatment. It is generally recommended to avoid live vaccines during this therapy.

Immunosuppressive medications: Drugs that suppress the immune system, such as corticosteroids (e.g., prednisone), may increase your risk of infections when used alongside Benralizumab. Your healthcare provider may adjust your dosage or closely monitor you to reduce the likelihood of complications.

Benralizumab in Pregnancy

Is it safe to take Benralizumab during pregnancy?

There is limited information available regarding the safety of Benralizumab use during pregnancy. While animal studies have not shown harm to the fetus, no well-controlled studies have been conducted in pregnant women. If you are pregnant or planning to become pregnant, it is essential to discuss the potential risks and benefits of Benralizumab treatment with your healthcare provider. They will help you carefully weigh the risks of untreated asthma or eosinophilic asthma against the potential risks of using this biologic therapy during pregnancy.

Benralizumab While Breastfeeding

Is it safe to take Benralizumab while breastfeeding?

It is currently unknown whether Benralizumab passes into breast milk. Since many medications can transfer to a nursing infant through breast milk, it is important to consult your healthcare provider if you are breastfeeding and considering Benralizumab treatment. Your doctor will work with you to determine whether to continue breastfeeding or discontinue the medication, taking into account your specific circumstances and the severity of your asthma.

Estimated Cost of Benralizumab Treatment

The cost of Benralizumab can vary based on factors such as your location, pharmacy, and insurance coverage. Without insurance, the estimated cost of a 30-day supply of Benralizumab ranges from $5,000 to $6,000 when using a GoodRx coupon. Prices may fluctuate, so it is advisable to check with your pharmacy or use a GoodRx coupon to find the most affordable option for this asthma biologic therapy.

Possible Alternatives to Benralizumab Treatment

If Benralizumab is not the right option for you, there are other treatments and lifestyle adjustments that may help manage your condition effectively. It’s important to consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine visit with one of our providers to explore these alternatives in detail.

Asthma Treatment Alternatives

Asthma: Alternative treatments include inhaled corticosteroids (e.g., Fluticasone), long-acting beta-agonists (e.g., Salmeterol), or leukotriene modifiers (e.g., Montelukast). In addition to medication, lifestyle changes—such as avoiding known asthma triggers, maintaining a healthy weight, and engaging in regular physical activity—can play a significant role in symptom management. Depending on your specific needs, these options may complement or replace biologic therapies for asthma.

Managing Eosinophilic Esophagitis

Eosinophilic esophagitis: Dietary modifications, such as eliminating specific allergens, and medications like proton pump inhibitors (e.g., Omeprazole) or corticosteroids (e.g., Budesonide), can be effective in managing this condition. Work closely with your healthcare provider to determine the most appropriate treatment plan for your situation.

Chronic Rhinosinusitis with Nasal Polyps Alternatives

Chronic rhinosinusitis with nasal polyps: Treatment options include nasal corticosteroids (e.g., Fluticasone nasal spray) or, in some cases, surgery to remove polyps. Additionally, avoiding allergens and using saline nasal rinses can help alleviate symptoms and improve overall nasal health.

Hypereosinophilia Treatment Options

Hypereosinophilia: Corticosteroids (e.g., Prednisone) or other immunosuppressive medications may be used as alternative treatments. Regular monitoring and addressing any underlying conditions are critical to managing this condition effectively.

Atopic Dermatitis Management

Atopic dermatitis: Treatment options include topical corticosteroids (e.g., Hydrocortisone), calcineurin inhibitors (e.g., Tacrolimus), or biologics like Dupilumab. In addition, maintaining a consistent skincare routine with regular moisturizing and avoiding irritants can significantly improve symptoms and prevent flare-ups.

Chronic Obstructive Pulmonary Disease (COPD) Alternatives

Chronic obstructive pulmonary disease (COPD): Alternatives include bronchodilators (e.g., Albuterol), inhaled corticosteroids (e.g., Budesonide), and lifestyle changes such as quitting smoking and participating in pulmonary rehabilitation programs. These options can be tailored to your specific condition and needs to optimize your quality of life.

Allergic Rhinitis Treatment Options

Allergic rhinitis: Antihistamines (e.g., Cetirizine), nasal corticosteroids (e.g., Fluticasone), and allergen avoidance strategies can effectively manage symptoms. Collaborate with your healthcare provider to identify the best combination of treatments for your individual needs.

Systemic Lupus Erythematosus Alternatives

Systemic lupus erythematosus: Immunosuppressive medications (e.g., Hydroxychloroquine) and lifestyle adjustments, such as practicing sun protection and engaging in regular, low-impact exercise, can help manage symptoms and enhance overall well-being.

Granulomatosis with Polyangiitis Management

Granulomatosis with polyangiitis: Common treatments include immunosuppressive medications (e.g., Methotrexate) and corticosteroids (e.g., Prednisone). Regular monitoring and proactive symptom management are essential for effective treatment and long-term disease control.

Churg-Strauss Syndrome Treatment Options

Churg-Strauss syndrome: Treatment often involves corticosteroids (e.g., Prednisone) and immunosuppressive medications (e.g., Cyclophosphamide). Consistent follow-ups with your healthcare provider are crucial to managing this condition and preventing complications.

Recent Updates on Benralizumab Research

Recent studies continue to highlight Benralizumab’s effectiveness in reducing asthma exacerbations in patients with severe eosinophilic asthma. Researchers are also exploring its potential use in other eosinophil-related conditions, such as eosinophilic esophagitis and chronic rhinosinusitis with nasal polyps. Additionally, ongoing investigations are examining whether Benralizumab could benefit patients with chronic obstructive pulmonary disease (COPD) who have elevated eosinophil levels. While these findings are promising, further research is needed to confirm its efficacy in these areas.

Staying informed about the latest advancements in treatment options is essential. If you have questions about Benralizumab or your current treatment plan, consider scheduling a telemedicine appointment with one of our providers. Together, you can explore the best options for managing your condition and improving your quality of life.

James Kingsley

Learn More